The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits

Anhedonia is a common, persistent, and disabling condition. However, available therapeutics primarily focus on the reduction of depressive and negative symptoms rather than amelioration of deficits in positive affect. As such, extant drug treatments remain largely ineffective in treating symptoms of...

Full description

Saved in:
Bibliographic Details
Published in:Psychopharmacology 2022-07, Vol.239 (7), p.2011-2039
Main Authors: Nogo, Danica, Jasrai, Ashitija K., Kim, Haeun, Nasri, Flora, Ceban, Felicia, Lui, Leanna M. W., Rosenblat, Joshua D., Vinberg, Maj, Ho, Roger, McIntyre, Roger S.
Format: Article
Language:English
Subjects:
Anhedonia
Biomedical and Life Sciences
Biomedicine
Care and treatment
Dosage and administration
Hedonic response
Ketamine
Medicine
Mental depression
Motivation
Neurobiology
Neurosciences
Pharmacology/Toxicology
Physiological aspects
Psychiatry
Psychological aspects
Psychopharmacology
Quality of life
Reinforcement
Review
Suicides & suicide attempts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anhedonia is a common, persistent, and disabling condition. However, available therapeutics primarily focus on the reduction of depressive and negative symptoms rather than amelioration of deficits in positive affect. As such, extant drug treatments remain largely ineffective in treating symptoms of anhedonia. Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia. However, the literature on the anti-anhedonic effects of ketamine is limited—especially within independent dimensions of this symptom domain. Herein, this review examined the impact of ketamine treatment on anhedonia and its dimensions on anticipatory, consummatory, and motivation-related reward deficits. Overall, the findings have shown a trend towards symptom reduction and/or improvements in anhedonia and their respective subdomains, in both human and preclinical studies, as well as its potential to provide additional benefit in reducing suicidality and improving quality-of-life. Although further research is required in understanding the long-term efficacy and mechanism, ketamine may provide an effective and rapid-acting therapeutic in an otherwise unmet domain.
ISSN:0033-3158
1432-2072
DOI:10.1007/s00213-022-06105-9